Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13256198 | 0.82 | GABRA1 (0.30) | — | |
| Hydrochloric Acid SCHEMBL7640665 | 0.81 | HRH1 (0.36) | — | |
| SCHEMBL16152408 | 0.80 | PDE3B (0.31) | PDE3BPDE3A | |
| Dexmedetomidine SCHEMBL119382 | 0.77 | ADRA2A (0.50) | — | |
| Dexmedetomidine SCHEMBL14861666 | 0.77 | ADRA2A (0.50) | — | |
| Dexmedetomidine SCHEMBL29431568 | 0.77 | ADRA2A (0.50) | — | |
| Medetomidine SCHEMBL787913 | 0.77 | ADRA2A (0.50) | — | |
| Medetomidine SCHEMBL26432 | 0.77 | ADRA2A (0.50) | — | |
| Medetomidine SCHEMBL18497244 | 0.77 | ADRA2A (0.50) | — | |
| Dexmedetomidine SCHEMBL12092460 | 0.77 | ADRA2A (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393800-B1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN INC (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2393800-B1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20110306635-A1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND /OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN ,INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306635-A1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND /OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN ,INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306635-A1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND /OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN ,INC. (US) | 2011-12-15 | — | — | US | disclosed |
| EP-2393800-A1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | Allergan, Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010091209-A1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010091209-A1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306635-A1 | PYRIDINE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA2B AND /OR ALPHA 2C ADRENERGIC RECEPTORS | ADRA2C, ADRB2, ADRA2B | CYP2A6 768/4885PDE3B 185/4885PDE3A 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.